Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202948 | 0.81 | OPRM1 (0.51) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL5558326 | 0.79 | OPRL1 (0.48) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL18845203 | 0.78 | ACHE (0.57) | SIGMAR1OPRL1OPRM1OPRK1DRD2 | |
| SCHEMBL13131356 | 0.77 | OPRM1 (0.47) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL484649 | 0.77 | OPRM1 (0.47) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL18845206 | 0.76 | CYP2D6 (0.48) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL6621178 | 0.75 | KMT2A (0.54) | CYP3A4MEN1ALDH1A1CYP2C9TSHR | |
| SCHEMBL2918565 | 0.74 | SIGMAR1 (0.65) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL6777379 | 0.73 | SIGMAR1 (0.60) | CYP3A4HSD17B10MEN1ALDH1A1CYP2C9 | |
| SCHEMBL11031885 | 0.73 | FUCA1 (0.51) | ALDH1A1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141887-A1 | CRYSTAL FORM OF DIAZASPIROPYRAN COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-3165530-B1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QILU PHARMACEUTICAL CO LTD (CN) | 2018-12-05 | — | — | EP | disclosed |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016000581-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | 南京明德新药研发股份有限公司 | 2016-01-07 | — | — | WO | disclosed |
| WO-2009097405-A2 | COMPOUNDS AND METHODS FOR PREPARING DIAZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | CYP3A4 1469/4885HSD17B10 1612/4885MEN1 3991/4885 |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | ALK, ROS1, ARSA | CYP3A4 1469/4885HSD17B10 1612/4885MEN1 3991/4885 |
| US-20230141887-A1 | CRYSTAL FORM OF DIAZASPIROPYRAN COMPOUND | GOT1, ORMDL3, PKD1 | CYP3A4 417/4885HSD17B10 1314/4885MEN1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.